Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs CVS Health Corp (CVS) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
CVS Health CorpTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs CVS Health Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.98 (market cap $29.60B), while CVS Health Corp trades at $93.39 (market cap $119.58B). The key difference: CVS Health Corp is far larger — about 4× Alnylam Pharmaceuticals, Inc.'s market cap, and CVS Health Corp pays a 2.84% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.

ALNYCVS
Market Cap
$29.60B$119.58B
Sector
HealthHealth
52-Week High
$491.22$110.60
52-Week Low
$205.48$65.51
Enterprise Value
$27.56B$181.93B
Dividend Yield
2.84%

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS